A Phase II Trial of Cetuximab (c225) as Therapy for Recurrent Non-Small Cell Lung Cancer in Patients Who Have Received Prior Therapy With Tyrosine Kinase Inhibitor Directed Against the EGFR Pathway
- Participants on this study will receive cetuximab by infusion intravenously once per
week and may continue to receive weekly cetuximab infusions until their disease
progresses or they experience unacceptable side effects.
- The following will be performed every 4 weeks while they are receiving study
treatments: Physical examination; performance status; and blood work. A CT scan of the
chest and upper abdomen will be performed every 8 weeks.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response Rate by CT Scan Using RECIST Criteria
Lecia Sequist, MD, MPH
Massachusetts General Hospital
United States: Institutional Review Board
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|